FLT3 V16L

CI-VAR-00004477Explore in graph →NP_004110.2:p.Val16LeuNM_004119.3:c.46G>CClinVar 134436 CIViC 5183

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Myeloid Neoplasm1
FLT3 V16L	(predisposing)	Predisposing	C	Supports Predisposition	2	submitted	EID12424 The variant was identified in at least 1/690 patients with myeloid malignancy but not assessed amongst 38821 HRC controls. PMID 31911633 · Li et al., 2020 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.